• Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMD
  • Positive recommendation is based on data from the LADDER, Archway and Portal studies showing Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections1-3
  • By continuously delivering medicine into the eye through the Contivue® refillable implant, Susvimo may help people with nAMD maintain their vision with as few as two treatments per year1-3
  • nAMD is a leading cause of blindness in people over the age of 60 and affects 1.7 million in the European Union (EU)4